Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cells

Cancer Immunology, Immunotherapy

Volumn 55, Issue 5, 2006, Pages 538-546

  Fukui, Mikiko ^a   Ueno, Koji ^a   Suehiro, Yutaka ^a   Hamanaka, Yuichiro ^a   Imai, Kohzoh ^b   Hinoda, Yuji ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

CD4 T cells; Centrosomal protein; Dendritic cells; MHC class II; mRNA; RHAMM

Indexed keywords

CANCER VACCINE; CELL PROTEIN; DENDRITIC CELL VACCINE; HYALURONAN MEDIATED MOTILITY RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IMMUNIZATION; INOCULATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN TRANSPORT; SPLEEN CELL; T CELL DEPLETION; TARGET CELL; TUMOR CELL;

ANIMALS; ANTIGENS, CD44; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 33645001096     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0027-4     Document Type: Article

References (56)

1. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ (1998) Centrosome defects and genetic instability in malignant tumors. Cancer Res 58:3974-3985
2. Nigg EA (2002) Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2:815-825
3. Charrasse S, Schroeder M, Gauthier-Roucviere C, Ango F, Cassimeris L, Gard DL, Larroque C (1998) The TOGp protein is a new human microtubule- associated protein homorogous to the Xenopus XMAP215. J Cell Sci 111:1371-1383
4. Wells RA, Catzavelos C, Kamel-Reid S (1997) Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 17:109-113
5. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052-3065
6. Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, Nojima T, Levin LS, Fujikawa-Yamamoto K, Suzuki K, Fukasawa (2004) Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res 64:4800-4809
7. Neben K, Tews B, Wrobel G, Hahn M, Kokocinski F, Giesecke C, Krause U, Ho AD, Kramer A, Lichter P (2004) Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. Oncogene 23:2379-2384
8. Maxwell AC, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E, Hendzel M, Chan G, Pilarski LM (2003) RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 14:2262-2276
9. Line A, Slucka Z, Stengrevics A, Li G, Rees RC (2002) Altered splicing pattern of TACC1 mRNA in gastric cancer. Cancer Genet Cytogenet 139:78-83
10. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G, Heilmann V, Gschwend J, Bergmann L, Dohner H, Schmitt M (2002) Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 30:1029-1035
11. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H, Schimitt M (2003) Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 106:224-231
12. Wang C, Thor AD, Moore DH II, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA (1998) The overexpression of RHAMM, a hyalurinan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 4:567-576
13. Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, Niimi A, Ueda M, Kimata K (1999) Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res 90:987-992
14. Crainie M, Belch AR, Mant MJ, Pilarski LM (1999) Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 93:1684-1696
15. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B Jr, Shaughnessy J, Reiman T (2004) RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 104:1151-1158
16. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Dohner H, Schmitt M (2004) mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 108:704-711
17. Assman V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AD (2001) The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumor cells. J Pathol 195:191-196
18. Li H, Guo L, Li JW, Liu N, Qi R, Liu J (2000) Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol 17:927-932
19. Kong QY, Liu J, Chen XY, Wang XW, Sun Y, Li H (2003) Differntiall expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep 10:51-55
20. Rein DT, Roehrig K, Schondorf T, Lazar A, Fleisch M, Niederacher D, Bender HG, Dall P (2003) Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumor progression and metastasis. J Cancer Res Clin Oncol 129:161-164
21. Turley EA, Noble PW, Bourguignon LY (2002) Signaling properties of hyaluronan receptors. J Biol Chem 277:4589-4592
22. Tolg C, Poon R, Fodde R, Turley EA, Alman BA (2003) Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene 22:6873-6882
23. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK (2003) Dendritic cells as a vectors for immunotherapy of cancer. Semin Cancer Biol 13:439-447
24. Yannelli JR, Wroblewski JM (2004) On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23:97-113
25. Schmidt T, Ziske C, Marten A, Endres S, Teimann K, Schmitz V, Gorschluter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG (2003) Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 63:8962-8967
26. Mitchell DA, Nair SK (2000) RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106:1065-1069
27. Ponsaerts P, van Tendeloo VF, Berneman ZN (2003) Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 134:378-384
28. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693-702
29. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells I metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288
30. Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR (1998) The human hyaluronan receptor RHAMM is expressed as an intracellular protein ini breast cancer cells. J Cell Sci 111:1685-1694
31. Fukui M, Nakano-Hashimoto T, Okano K, Maruta Y, Suehiro Y, Hamanaka Y, Yamashita H, Imai K, Hinoda Y (2004) Therapeutic effect of dendritic cells loaded with a fusion mRNA encoding tyrosinase-related protein 2 and enhanced green fluorescence protein on B16 melanoma. Tumour Biol 25:252-257
32. Son YI, Egawa S, Tatsumi T, Redlinger RE Jr, Kalinski K, Kanto T (2002) A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 262:145-157
33. Okano K, Fukui M, Suehiro Y, Hamanaka Y, Imai K, Hinoda Y (2003) Evaluation of an mRNA lipofection procedure for human dendritic cells and induction of cytotoxic T lymphocytes against enhanced green fluorescence protein. Tumour Biol 24:317-324
34. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A (1994) Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153:2102-2109
35. Adachi T, Hinoda Y, Nishimori I, Adachi M, Imai K (1997) Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase. J Immunol 159:2645-2651
36. Hofmann M, Fieber C, Assmann V, Gottlicher M, Sleeman J, Plug R, Howells N, von Stein O, Ponta H, Herrlich P (1998) Identification of IHABP, a 95 kDa intracellular hyaluronate binding protein. J Cell Sci 111:1673-1684
37. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S, Lange LA, Wang C, Curpen GD, Savani RC, Greenberg AH, Turley EA (1995) Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 82:19-26
38. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM (1995) Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:11671-11675
39. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J (2002) Enhanced induction of telomerase-specific CD4 (+) T cells using dendritic cells transfected ith RNA encoding a chimeric gene product. Cancer Res 62:5041-5048
40. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steiman RM (2000) The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompaibility complex class II-positive lysosomal compartments. J Cell Biol 151:673-684
41. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K (2003) Efficient presentation f known HLA class II-restricted MAGE-A3 epitope by dendritic cells electroporated with messenger RNA encoding an invariant chain with genentic exchange of class II-associated invariant chain peptide. Cancer Res 63:5587-5594
42. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E (1994) The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152:2324-2332
43. Grohmann U, Fioretti MC, Bianchi R, Belladonna ML, Ayroldi E, Surace D, Silla S, Puccetti P (1998) Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. Crit Rev Immunol 18:87-98
44. + T cells in the antitumor immune response. J Exp Med 188:2357-2368
45. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA 96:8633-8638
46. + T cells without induction of phthisis. J Immunol 167:5832-5837
47. Hahn S, Erb P (1999) The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes in health and disease. Int Rev Immunol 18:449-464
48. Kataoka T, Ito M, Budd RC, Tschopp J, Nagai K (2002) Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells. Exp Cell Res 273:256-264
49. van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA (2003) Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 171:5842-5852
50. Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells. Immunity 12:677-686
51. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN (1996) Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93:14809-14814
52. Steitz J, Bruck J, Steinbrink K, Fnk A, Knop J, Tuting T (2000) Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 86:89-94
53. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167:7150-7156
54. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhause AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD (2003) Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9:1284-1290
55. Gavanescu I, Pihan G, Halilovic E, Szomolanyi-Tsuda E, Welsh RM, Doxsey S (2004) Mycoplasma infection induces a scleroderma-like centrosome autoantibody response in mice. Clin Exp Immunol 137:288-297
56. Gavanescu I, Vazquez-Abad D, McCauley J, Senecal J-L, Doxsey S (1999) Centrosome proteins: a major class of autoantigens in scleroderma. J Clin Immunol 19:166-171